

INDEX OF APPROVED BIOSIMILARS

The Biologics Prescribers Collaborative appreciates FDA's careful deliberation before approving biosimilar applicants. As of May 2019, there are 19 approved biosimilars, with additional approvals expected. For further information, please reference the Purple Book on FDA's site.

Biosimilar Product (Proprietary Name)	FDA Approval Date	U.S. Launch Date	FDA Approved Indications
filgrastim-sndz Biosimilar: Zarxio (Sandoz) Reference biologic: Neupogen (Amgen)	March 2015	September 2015	<ul style="list-style-type: none"> Patients with cancer receiving myelosuppressive chemotherapy Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy Patients with cancer undergoing bone marrow transplantation Patients undergoing autologous peripheral blood progenitor cell collection and therapy Patients with severe chronic neutropenia
infliximab-dyyb Biosimilar: Inflectra (Celltrion) Reference biologic: Remicade (Janssen)	April 2016	November 2016	<ul style="list-style-type: none"> Adult patients and pediatric patients (ages six years and older) with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy Patients with moderately to severely active rheumatoid arthritis in combination with methotrexate Patients with active ankylosing spondylitis (arthritis of the spine) Patients with active psoriatic arthritis Adult patients with chronic severe plaque psoriasis
etanercept-szzs Biosimilar: Erelzi (Sandoz) Reference biologic: Enbrel (Amgen)	August 2016	TBD	<ul style="list-style-type: none"> Moderate to severe rheumatoid arthritis, either as a standalone therapy or in combination with methotrexate (MTX) Moderate to severe polyarticular juvenile idiopathic arthritis in patients ages two and older Active psoriatic arthritis, including use in combination with MTX in psoriatic arthritis patients who do not respond adequately to MTX alone Active ankylosing spondylitis (an arthritis that affects the spine) Chronic moderate to severe plaque psoriasis in adult patients (18 years or older) who are candidates for systemic therapy or phototherapy
adalimumab-atto Biosimilar: Amjevita (Amgen) Reference biologic: Humira (AbbVie)	September 2016	January 2023	<ul style="list-style-type: none"> Moderately to severely active rheumatoid arthritis Active psoriatic arthritis Active ankylosing spondylitis (an arthritis that affects the spine) Moderately to severely active Crohn's disease Moderately to severely active ulcerative colitis Moderate to severe plaque psoriasis
infliximab-abda Biosimilar: Renflexis (Samsung Bioepis / Merck) Reference biologic: Remicade (Janssen)	May 2017	July 2017	<ul style="list-style-type: none"> Who have had an inadequate response to conventional therapy Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy Patients with moderately to severely active rheumatoid arthritis in combination with methotrexate Patients with active ankylosing spondylitis (arthritis of the spine) Patients with active psoriatic arthritis Adult patients with chronic severe plaque psoriasis

INDEX OF APPROVED BIOSIMILARS

Biosimilar Product (Proprietary Name)	FDA Approval Date	FDA Launch Date	FDA Approved Indications
adalimumab-adbm Biosimilar: Cyltezo (Boehringer Ingelheim) Reference biologic: Humira (AbbVie)	August 2017	November 2023	<ul style="list-style-type: none"> Adult patients with moderately to severely active rheumatoid arthritis Moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older Adult patients with active psoriatic arthritis Adult patients with active ankylosing spondylitis Adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine Adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy
bevacizumab-awwb Biosimilar: Mvasi (Amgen/Allergan) Reference biologic: Avastin (Genentech)	September 2017	July 2019	<ul style="list-style-type: none"> Patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil-based chemotherapy Patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab product-containing regimen First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel Treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent Treatment of metastatic renal cell carcinoma in combination with interferon alfa Treatment of persistent, recurrent, or metastatic carcinoma of the cervix in combination with paclitaxel and cisplatin or paclitaxel and topotecan
trastuzumab-dkst Biosimilar: Ogivri (Mylan/Biocon) Reference biologic: Herceptin (Roche)	December 2017	June 2019	<ul style="list-style-type: none"> Adjuvant treatment of HER2-overexpressing node positive or node negative (EP/PR negative or with one high risk feature) breast cancer As a single agent or in combination with paclitaxel for HER2-overexpressing metastatic breast cancer In combination with cisplatin and capecitabine or 5-fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease
infliximab-qbtx Biosimilar: Ixifi (Pfizer) Reference biologic: Remicade (Johnson & Johnson)	December 2017	TBD	<ul style="list-style-type: none"> Adult patients and pediatric patients (6 years of age and older) with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy Patients with moderately to severely active rheumatoid arthritis in combination with methotrexate Patients with active ankylosing spondylitis (arthritis of the spine) Patients with active psoriatic arthritis Adult patients with chronic severe plaque psoriasis

INDEX OF APPROVED BIOSIMILARS

Biosimilar Product (Proprietary Name)	FDA Approval Date	U.S. Launch Date	FDA Approved Indications
<p>epoetin alfa-epbx</p> <p>Biosimilar: Retacrit (Pfizer/Hospira)</p> <p>Reference biologic: Epogen/Procrit (Amgen)</p>	May 2018	November 2018	<p>Treatment of anemia due to:</p> <ul style="list-style-type: none"> Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis Zidovudine in patients with HIV-infection The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of unplanned chemotherapy Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery
<p>pegfilgrastim-jmdb</p> <p>Biosimilar: Fulphila (Mylan/Biocon)</p> <p>Reference biologic: Neulasta (Amgen)</p>	June 2018	July 2018	<ul style="list-style-type: none"> Patients with cancer receiving myelosuppressive chemotherapy to decrease the incidence of infection, as manifested by febrile neutropenia Patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
<p>filgrastim-aafi</p> <p>Biosimilar: Nivestym (Pfizer)</p> <p>Reference biologic: Neupogen (Amgen)</p>	July 2018	October 2018	<ul style="list-style-type: none"> Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML Patients with cancer undergoing bone marrow transplantation Patients undergoing autologous peripheral blood progenitor cell collection and therapy Patients with congenital neutropenia Patients with cyclic or idiopathic neutropenia
<p>adalimumab-adaz</p> <p>Biosimilar: Hyrimoz (Sandoz)</p> <p>Reference biologic: Humira (AbbVie)</p>	October 2018	September 2023	<ul style="list-style-type: none"> Adult patients with rheumatoid arthritis Pediatric patients (4 years of age and older) with juvenile idiopathic arthritis Adult patients with psoriatic arthritis Adult patients with ankylosing spondylitis Adult patients with adult Crohn's disease Adult patients with moderately to severely active ulcerative colitis Adult patients with moderate to severe chronic plaque psoriasis
<p>pegfilgrastim-cbqv</p> <p>Biosimilar: Udenyca (Coherus Biosciences)</p> <p>Reference biologic: Neulasta (Amgen)</p>	November 2018	TBD	<ul style="list-style-type: none"> Patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia to decrease the incidence of infection, as manifested by febrile neutropenia

INDEX OF APPROVED BIOSIMILARS

Biosimilar Product (Proprietary Name)	FDA Approval Date	U.S. Launch Date	FDA Approved Indications
rituximab-abbs Biosimilar: Truxima (Celltrion/Teva) Reference biologic: Rituxan (Roche)	November 2018	TBD	<ul style="list-style-type: none"> Adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent Adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy Adult patients with non-progressing (including stable disease), low-grade, CD20 positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine and prednisone (CVP) chemotherapy
trastuzumab-pkrb Biosimilar: Herzuma (Celltrion/Teva) Reference biologic: Herceptin (Roche)	December 2018	TBD	<p>Adjuvant Breast Cancer of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer:</p> <ul style="list-style-type: none"> As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel As part of a treatment regimen with docetaxel and carboplatin Metastatic Breast Cancer: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
trastuzumab-dttb Biosimilar: Ontruzant (Samsung Bioepis) Reference biologic: Herceptin (Roche)	January 2019	TBD	<p>Adjuvant Breast Cancer of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer:</p> <ul style="list-style-type: none"> As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel As part of a treatment regimen with docetaxel and carboplatin Metastatic Breast Cancer: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
trastuzumab-qyyp Biosimilar: Trazimera (Pfizer, Inc.) Reference biologic: Herceptin (Roche)	March 2019	TBD	<p>Adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high-risk feature) breast cancer</p> <ul style="list-style-type: none"> As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel As part of a treatment regimen with docetaxel and carboplatin A single agent following multi-modality, anthracycline-based therapy <p>In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease In combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease</p>

INDEX OF APPROVED BIOSIMILARS

Biosimilar Product (Proprietary Name)	FDA Approval Date	U.S. Launch Date	FDA Approved Indications
<p>etanercept-ykro</p> <p>Biosimilar: Eticovo (Samsung Bioepis Co., Ltd.)</p> <p>Reference Biologic: Enbrel (Amgen Inc.)</p>	April 2019	TBD	<ul style="list-style-type: none"> Moderately to severely active rheumatoid arthritis <ul style="list-style-type: none"> As a standalone therapy or in combination with methotrexate Moderately to severely active polyarticular juvenile idiopathic arthritis <ul style="list-style-type: none"> In patients 2 years of age or older Active psoriatic arthritis <ul style="list-style-type: none"> With or without methotrexate Active ankylosing spondylitis (an arthritis that affects the spine) Chronic moderate to severe plaque psoriasis <ul style="list-style-type: none"> In patients 4 years of age or older who are candidates for systemic therapy or phototherapy